Multiple Sclerosis Pipeline Outlook, FDA Approvals, Clinical Trials And Companies 2024 (Updated)

(MENAFN- GetNews)

DelveInsight's,
“Multiple sclerosis Pipeline Insight 2024”
report provides comprehensive insights about
100+ companies and 100+ pipeline drugs
in Multiple sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Multiple Sclerosis Pipeline Report

• DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Multiple Sclerosis treatment.
• The leading Multiple Sclerosis Companies working in the market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Promising Multiple Sclerosis Therapies in the various stages of development include 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others
• May 2024: SYSNAV- Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis (NHS-MS-EGYPT). The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.
• May 2024:- Clene Nanomedicine- A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis. A total of two treatment cohorts may be studied. Investigators and patients will remain blinded to study dose until the study database is formally locked. All patients will receive daily oral treatment over twelve (12) consecutive weeks during each cohort's Treatment Period.

Request a sample and discover the recent advances in Multiple Sclerosis treatment drugs @ Multiple Sclerosis Pipeline Outlook Report

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain. MS is unpredictable and affects each patient differently – some individuals may be mildly affected, while others may lose their ability to write, speak or walk.

Multiple Sclerosis Emerging Drugs Profile

• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION

Find out more about Multiple Sclerosis treatment drugs @ Drugs for Multiple Sclerosis Treatment

Multiple Sclerosis Therapeutics Assessment

There are approx. 100+ key Multiple Sclerosis companies which are developing the therapies for Multiple sclerosis. The Multiple Sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.

DelveInsight's Multiple Sclerosis pipeline report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Learn more about the emerging Multiple Sclerosis pipeline therapies @ Multiple Sclerosis Clinical Trials

Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Multiple Sclerosis Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Multiple Sclerosis Companies

TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others

Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, visit @ Multiple Sclerosis Drugs

Scope of the Multiple Sclerosis Pipeline Report

• Coverage- Global
• Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others
• Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others

For further information on the Multiple Sclerosis Pipeline Therapeutics, reach out @ Multiple Sclerosis Treatment Drugs

Table of Content

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.